ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,190 GBX | +1.35% |
|
-0.86% | +15.00% |
| 31/05 | Health Care Stocks Climb On Drug News -- Health Care Roundup | DJ |
| 31/05 | Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal | MT |
| Sales 2024 * | 51.62B 4,306B | Sales 2025 * | 55.5B 4,629B | Capitalization | 240B 20,056B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.84B 738B | Net income 2025 * | 10.38B 866B | EV / Sales 2024 * | 5.05 x |
| Net Debt 2024 * | 20.42B 1,703B | Net Debt 2025 * | 13.71B 1,144B | EV / Sales 2025 * | 4.58 x |
| P/E ratio 2024 * |
27.4
x | P/E ratio 2025 * |
23.3
x | Employees | 89,900 |
| Yield 2024 * |
1.98% | Yield 2025 * |
2.09% | Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +1.35% | ||
| 1 week | -0.86% | ||
| 1 month | +1.06% | ||
| 3 months | +22.11% | ||
| 6 months | +20.38% | ||
| Current year | +15.00% |
1 week
11 858.00
12 266.00
1 month
11 858.0012 450.00
Current year
9 461.0012 488.00
1 year
9 461.0012 488.00
3 years
7 870.0012 488.00
5 years
5 739.0012 488.00
10 years
3 680.0012 488.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01/12/01 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01/21/01 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01/17/01 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01/13/01 |
Philip Broadley
BRD | Director/Board Member | 63 | 27/17/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 200 M€ | +16.70% | ||
| 5.17% | 17 M€ | +6.09% | - | |
| 4.89% | 693 M€ | +12.25% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 12,190 | +1.35% | 4,183,291 |
| 30/24/30 | 12,028 | +0.82% | 1,694,794 |
| 29/24/29 | 11,930 | -0.81% | 2,028,915 |
| 28/24/28 | 12,028 | -2.18% | 2,196,897 |
| 24/24/24 | 12,296 | -0.87% | 919,468 |
Delayed Quote London S.E., May 31, 2024 at 09:05 pm IST
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.00% | 240B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- AZN Stock
